HPV Vaccine Approval for Women Over 50
The HPV vaccine is NOT approved for use in women over age 50. The FDA-approved age range for the 9-valent HPV vaccine (Gardasil 9) extends only from 9 through 45 years of age 1.
Regulatory Approval and Age Limits
In October 2018, the FDA expanded the approved age range for 9vHPV from 9-26 years to 9-45 years maximum in both women and men 1. This represents the upper limit of licensure—HPV vaccines are not licensed for use in adults aged >45 years 1, 2.
Clinical Recommendations for Different Age Groups
Ages 27-45 Years (Not Over 50)
Even within the approved age range of 27-45 years, ACIP does not recommend routine catch-up vaccination for all adults. Instead, they recommend:
- Shared clinical decision-making for some adults aged 27-45 who are not adequately vaccinated and may be at risk for new HPV infection 1, 2
- Recognition that most adults in this age range have already been exposed to HPV, limiting vaccine benefit
- Individual consideration based on ongoing risk of new HPV exposure
Why the Age 45 Cutoff Exists
The limitation stems from:
- Clinical trial data that only extended through age 45 1
- Diminishing benefit with increasing age due to prior HPV exposure 3, 4
- Cost-effectiveness concerns beyond the late 20s 3
- Most HPV acquisition occurs soon after sexual debut, with highest rates in adolescents and young adults 1
Key Clinical Pitfalls
Do not prescribe HPV vaccine to women over age 45—this is off-label use without supporting efficacy or safety data in this population. The vaccine approval was based on bridging immunogenicity and safety data that only extended to age 45 1.
For women over 50, the focus should remain on cervical cancer screening according to established guidelines rather than vaccination 2.